GSK Says Still In Dark About Nature Of China 'Economic Crimes' Probe
This article was originally published in PharmAsia News
A weekend after its employees were detained or ousted from three offices in China, GlaxoSmithKline said it still did not know "the precise nature" of investigations of senior managers for "economic crimes."
You may also be interested in...
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.